A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
about
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesAddition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks.Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetesWeight considerations in pharmacotherapy for type 2 diabetesHD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies.Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled studyOutcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus.The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus.A review of gliptins in 2011.Cardiovascular effects of gliptins.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.A Novel Allosteric Insulin Receptor-Activating Antibody Reduces Hyperglycemia without Hypoglycemia in Diabetic Cynomolgus Monkeys.Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight.Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis.
P2860
Q24628948-C7E661ED-206B-436F-9903-645456BBB916Q33603409-06425BAA-94EB-4485-B241-37D8165D1B14Q33603551-D23F35E2-C228-49B2-966A-6F8D02154377Q33607755-1CD36BC1-8497-424F-BCB2-5AA80523FE0CQ34159414-72A3774A-5A89-4EF7-A016-F4F1AA4816E4Q34360545-D868F63A-3E78-49F5-8893-26070F778CF3Q34586376-967DAC0A-B30D-4D47-8910-3F6DEE2FB09DQ36975695-A3A09CB2-323B-4D45-B57B-9C577C5CB47BQ37010393-176A9E0D-8F20-4127-987A-E12B8955098AQ37412882-0D62A664-2B78-4A2D-A760-BDBC54D973E0Q37502106-A507AB36-86ED-4356-B300-2EA9B931A711Q37965612-ED11181B-F3BE-4BF2-9C49-7EF2C8DAB0C8Q38072259-C079E111-DA1C-43AA-AC1D-CFC09CC9C77BQ38113092-42D721BC-D333-4BDD-AF95-6CE6930A42D3Q40311070-E08C2472-BD78-409D-ABC7-53E375C55864Q42171159-E98C5925-9731-4B28-BB8A-E7A49B1E95E5Q42575070-D98D1255-6E61-4802-96C2-822C261158F3Q44500493-845C8B3E-AC9E-4410-905D-4421E317091DQ45218410-47B3E8F7-153D-40C6-B3EF-FA61AB7BC7A6Q51301791-D1E6CE47-C2A5-4B87-8F1D-94DA3B4D6713
P2860
A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A review of the effects of ant ...... f incretin targeted therapies.
@en
type
label
A review of the effects of ant ...... f incretin targeted therapies.
@en
prefLabel
A review of the effects of ant ...... f incretin targeted therapies.
@en
P2093
P356
P1476
A review of the effects of ant ...... f incretin targeted therapies.
@en
P2093
Anthony Barnett
Josie Allsworth
Kevin Jameson
Rachel Mann
P304
P356
10.1185/030079907X199691
P407
P577
2007-07-01T00:00:00Z